Recombinants in Thrombosis and Hemostasis: From Basic Research to Clinical Therapy

Giuseppe Lippi; Emmanuel J Favaloro

doi:10.1055/s-0030-1255440

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2010; 36(5): 471-476
DOI: 10.1055/s-0030-1255440

PREFACE

Recombinants in Thrombosis and Hemostasis: From Basic Research to Clinical Therapy

Giuseppe Lippi¹ , Emmanuel J. Favaloro²

¹U.O. Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
²Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, Australia

Abstract

Volltext

Referenzen

REFERENCES

1 Bowman L J, Anderson C D, Chapman W C. Topical recombinant human thrombin in surgical hemostasis. Semin Thromb Hemost. 2010; 36(5) 477-484
2 Favaloro E J, Posen J, Ramakrishna R et al.. Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. Blood Coagul Fibrinolysis. 2004; 15(8) 637-647
3 Lawson J H. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost. 2006; 32(Suppl 1) 98-110
4 Guideline on the clinical investigation of plasma derived fibrin sealant/haemostatic products (CPMP/BPWG/1089/00). Committee for medicinal products for human use (CHMP). European Medicines Agency. Available at: http://www.ema.europa.eu/pdfs/human/bpwg/108900en.pdf Accessed April 24, 2010
5 Franchini M, Lippi G. Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Hemost. 2010; 36(5) 485-492
6 Franchini M, Manzato F, Salvagno G L, Montagnana M, Zaffanello M, Lippi G. Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII. Semin Thromb Hemost. 2009; 35(8) 814-819
7 Franchini M, Franchi M, Bergamini V, Salvagno G L, Montagnana M, Lippi G. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Semin Thromb Hemost. 2008; 34(1) 104-112
8 Franchini M, Favaloro E J, Lippi G. Glanzmann thrombasthenia: an update. Clin Chim Acta. 2010; 411(12) 1-6
9 Franchini M, Lippi G. Recombinant factor VIII concentrates. Semin Thromb Hemost. 2010; 36(5) 493-497
10 Gouw S C, van den Berg H M. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost. 2009; 35(8) 723-734
11 Favaloro E J. Identification, pathogenesis, and treatment of factor inhibitors. Semin Thromb Hemost. 2009; 35(8) 719-722
12 Ananyeva N M, Lee T K, Jain N, Shima M, Saenko E L. Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents. Semin Thromb Hemost. 2009; 35(8) 735-751
13 Franchini M, Lippi G. Recent improvements in the clinical treatment of coagulation factor inhibitors. Semin Thromb Hemost. 2009; 35(8) 806-813
14 Mathews V, Nair S C, David S, Viswabandya A, Srivastava A. Management of hemophilia in patients with inhibitors: the perspective from developing countries. Semin Thromb Hemost. 2009; 35(8) 820-826
15 Lippi G, Franchini M, Favaloro E J. One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin. Blood Coagul Fibrinolysis. 2009; 20 1-3
16 Viiala N O, Larsen S R, Rasko J E. Gene therapy for hemophilia: clinical trials and technical tribulations. Semin Thromb Hemost. 2009; 35(1) 81-92
17 Monahan P E, Di Paola J. Recombinant factor IX for clinical and research use. Semin Thromb Hemost. 2010; 36(5) 498-509
18 Plaimauer B, Schlokat U, Turecek P L et al.. Recombinant von Willebrand factor: preclinical development. Semin Thromb Hemost. 2001; 27(4) 395-403
19 Schwarz H P, Schlokat U, Mitterer A et al.. Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease. Semin Thromb Hemost. 2002; 28(2) 215-226
20 Zhou Z, Nguyen T C, Guchhait P, Dong J F. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Thromb Hemost. 2010; 36(1) 71-81
21 Franchini M, Mannucci P M. Von Willebrand factor: another janus-faced hemostasis protein. Semin Thromb Hemost. 2008; 34(7) 663-669
22 Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost. 2007; 33(8) 787-797
23 Favaloro E J. Toward a new paradigm for the identification and functional characterization of von Willebrand disease. Semin Thromb Hemost. 2009; 35(1) 60-75
24 Turecek P L, Schrenk G, Rottensteiner H, Varadi K, Bevers E, Lenting P, Ilk N, Sleytr U B, Ehrlich H J, Schwarz H P. Structure and function of a recombinant von Willebrand factor (VWF) drug candidate. Semin Thromb Hemost. 2010; 36(5) 510-521
25 Muchitsch E, Dietrich B, Rottensteiner H, Auer W, Nehrbass D, Gritsch H, Ehrlich H J, Turecek P L, Schwarz H P. Pre-clinical testing of human recombinant von Willebrand factor: ADAMTS13 cleavage capacity in animals as criterion for species suitability. Semin Thromb Hemost. 2010; 36(5) 522-528
26 Douma R A, Kamphuisen P W. Thrombolysis for pulmonary embolism and venous thrombosis: is it worthwhile?. Semin Thromb Hemost. 2007; 33(8) 821-828
27 Campbell J, Hilleman D E. Recombinant peptides in thrombolysis. Semin Thromb Hemost. 2010; 36(5) 529-536
28 Lippi G, Franchini M, Favaloro E J. Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost. 2010; 36(5) 537-549
29 Levi M, Lowenberg E, Meijers J C. Recombinant anticoagulant factors for adjunctive treatment of sepsis. Semin Thromb Hemost. 2010; 36(5) 550-557
30 Lippi G, Favaloro E J. Recombinant platelet factor 4: a therapeutic, anti-neoplastic chimera?. Semin Thromb Hemost. 2010; 36(5) 558-569
31 Lippi G, Plebani M, Franchini M, Guidi G C, Favaloro E J. Prostate-specific antigen, prostate cancer, and disorders of hemostasis. Semin Thromb Hemost. 2009; 35(7) 654-664
32 Franchini M, Montagnana M, Favaloro E J, Lippi G. The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread. Semin Thromb Hemost. 2009; 35(7) 644-653
33 Snyder K M, Kessler C M. The pivotal role of thrombin in cancer biology and tumorigenesis. Semin Thromb Hemost. 2008; 34(8) 734-741
34 Miesbach W. Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment. Semin Thromb Hemost. 2008; 34(3) 282-285
35 Lechner D, Weltermann A. Chemotherapy-induced thrombosis: a role for microparticles and tissue factor?. Semin Thromb Hemost. 2008; 34(2) 199-203
36 Nadir Y, Vlodavsky I, Brenner B. Heparanase, tissue factor, and cancer. Semin Thromb Hemost. 2008; 34(2) 187-194
37 Milsom C, Yu J, May L, Magnus N, Rak J. Diverse roles of tissue factor-expressing cell subsets in tumor progression. Semin Thromb Hemost. 2008; 34(2) 170-181
38 Signaevsky M, Hobbs J, Doll J, Liu N, Soff G A. Role of alternatively spliced tissue factor in pancreatic cancer growth and angiogenesis. Semin Thromb Hemost. 2008; 34(2) 161-169
39 Palumbo J S. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost. 2008; 34(2) 154-160
40 Schaffner F, Ruf W. Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost. 2008; 34(2) 147-153
41 Rickles F R, Brenner B. Tissue factor and cancer. Semin Thromb Hemost. 2008; 34(2) 143-145